Psoriasiform lesions as a side effect of SGLT-2 therapy
SGLT-2 inhibitors (flozins) are one of the new classes of anti-diabetic drugs, used from 2012. They are highly recommended in case of intolerance or contraindication of metformin, but in Poland they are used usually as third-line drug after metformin and sulfonylurea. They growing popularity is cau...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nicolaus Copernicus University in Toruń
2023-01-01
|
| Series: | Quality in Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/QS/article/view/41832 |
| _version_ | 1797950952549908480 |
|---|---|
| author | Jakub Krzysztof Gałązka Łukasz Domagalski Piotr Homa Zofia Hoffman |
| author_facet | Jakub Krzysztof Gałązka Łukasz Domagalski Piotr Homa Zofia Hoffman |
| author_sort | Jakub Krzysztof Gałązka |
| collection | DOAJ |
| description |
SGLT-2 inhibitors (flozins) are one of the new classes of anti-diabetic drugs, used from 2012. They are highly recommended in case of intolerance or contraindication of metformin, but in Poland they are used usually as third-line drug after metformin and sulfonylurea. They growing popularity is caused by their significance in cardiovascular risk reduction and preventive role in according to diabetes complications like chronic kidney disease, or diabetes-induced dementia. The aid of this article is to summarize the knowledge on the risk of psoriasis development in diabetic patients cured with flozins.
In according to the newest studies, flozins may be considered as a pro-psoriatic factor, increasing the risk of this skin disease, especially in patients with diabetic kidney disease. But on the other hand, SGLT-2 inhibitors have significantly decreasing effect on cardiovascular risk, which is increased in psoriatic patients.
|
| first_indexed | 2024-04-10T22:24:17Z |
| format | Article |
| id | doaj.art-815bdb8726d640379d91838820bd58fb |
| institution | Directory Open Access Journal |
| issn | 2450-3118 |
| language | English |
| last_indexed | 2024-04-10T22:24:17Z |
| publishDate | 2023-01-01 |
| publisher | Nicolaus Copernicus University in Toruń |
| record_format | Article |
| series | Quality in Sport |
| spelling | doaj.art-815bdb8726d640379d91838820bd58fb2023-01-17T11:48:45ZengNicolaus Copernicus University in ToruńQuality in Sport2450-31182023-01-019110.12775/QS.2023.09.01.004Psoriasiform lesions as a side effect of SGLT-2 therapyJakub Krzysztof Gałązka0Łukasz Domagalski1Piotr Homa2Zofia Hoffman3Students’ Scientific Association at the Department and Clinic of Endocrinology, Diabetology and Metabolic Diseases, Medical University of LublinStudents’ Scientific Association at Department and Clinic of Neurosurgery and Pediatric Neurosurgery, Medical University of LublinStudents’ Scientific Association at the Department of Pediatric Hematology, Oncology and Transplantation, Medical University of LublinStudents’ Scientific Association at Chair of Human Anatomy, Medical University of Lublin SGLT-2 inhibitors (flozins) are one of the new classes of anti-diabetic drugs, used from 2012. They are highly recommended in case of intolerance or contraindication of metformin, but in Poland they are used usually as third-line drug after metformin and sulfonylurea. They growing popularity is caused by their significance in cardiovascular risk reduction and preventive role in according to diabetes complications like chronic kidney disease, or diabetes-induced dementia. The aid of this article is to summarize the knowledge on the risk of psoriasis development in diabetic patients cured with flozins. In according to the newest studies, flozins may be considered as a pro-psoriatic factor, increasing the risk of this skin disease, especially in patients with diabetic kidney disease. But on the other hand, SGLT-2 inhibitors have significantly decreasing effect on cardiovascular risk, which is increased in psoriatic patients. https://apcz.umk.pl/QS/article/view/41832flozinsSGLT-2 inhibitorspsoriasisdiabetesdiabetic kidney diseasediabetology |
| spellingShingle | Jakub Krzysztof Gałązka Łukasz Domagalski Piotr Homa Zofia Hoffman Psoriasiform lesions as a side effect of SGLT-2 therapy Quality in Sport flozins SGLT-2 inhibitors psoriasis diabetes diabetic kidney disease diabetology |
| title | Psoriasiform lesions as a side effect of SGLT-2 therapy |
| title_full | Psoriasiform lesions as a side effect of SGLT-2 therapy |
| title_fullStr | Psoriasiform lesions as a side effect of SGLT-2 therapy |
| title_full_unstemmed | Psoriasiform lesions as a side effect of SGLT-2 therapy |
| title_short | Psoriasiform lesions as a side effect of SGLT-2 therapy |
| title_sort | psoriasiform lesions as a side effect of sglt 2 therapy |
| topic | flozins SGLT-2 inhibitors psoriasis diabetes diabetic kidney disease diabetology |
| url | https://apcz.umk.pl/QS/article/view/41832 |
| work_keys_str_mv | AT jakubkrzysztofgałazka psoriasiformlesionsasasideeffectofsglt2therapy AT łukaszdomagalski psoriasiformlesionsasasideeffectofsglt2therapy AT piotrhoma psoriasiformlesionsasasideeffectofsglt2therapy AT zofiahoffman psoriasiformlesionsasasideeffectofsglt2therapy |